Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Introduction To Survival Analysis01:18

Introduction To Survival Analysis

221
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
221
Cancer Survival Analysis01:21

Cancer Survival Analysis

345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

177
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
177
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

125
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
125
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

124
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
124

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tumor-stroma proportion on primary tumor as a prognostic biomarker in advanced ovarian cancer patients receiving chemo-immunotherapy as first-line therapy: analyses from the NeoPembrOV/GINECO phase II randomized trial.

ESMO open·2025
Same author

Diagnostic and prognostic yields of ambulatory blood pressure measurements in haemodialysis patients: a 6-year longitudinal study.

Acta cardiologica·2024
Same author

Evaluation of Clinical Meaningfulness of Fortasyn Connect in Terms of "Time Saved".

The journal of prevention of Alzheimer's disease·2024
Same author

The pattern of cortical thickness associated with executive dysfunction in MCI and SCC: The MEMENTO cohort.

Revue neurologique·2024
Same author

Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU): Trial Satisfaction and Attitudes towards Future Clinical Trials.

The journal of prevention of Alzheimer's disease..·2024
Same author

T1w/FLAIR ratio standardization as a myelin marker in MS patients.

NeuroImage. Clinical·2022

Related Experiment Video

Updated: Jun 27, 2025

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS
06:49

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS

Published on: October 6, 2015

19.7K

"Time Saved" Calculations to Improve Decision-Making in Progressive Disease Studies.

S P Dickson1, B Haaland, C H Mallinckrodt

  • 1Achim Schneeberger, Advantage Therapeutics, 195 NW 40th St, Miami, FL 33127 United States, achim.schneeberger@advantagetherapeutics.com, +43 69911098989.

The Journal of Prevention of Alzheimer'S Disease
|May 6, 2024
PubMed
Summary

Time component tests (TCTs) demonstrated an 11-month time savings in Alzheimer's disease treatment, offering a clearer interpretation of disease-modifying therapies (DMTs) compared to standard composite outcomes.

Keywords:
AFFITOPE® AD02Alzheimer’s diseaseIMM-AD04disease modifying agentstime saved

More Related Videos

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

11.1K
Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

400

Related Experiment Videos

Last Updated: Jun 27, 2025

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS
06:49

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS

Published on: October 6, 2015

19.7K
Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

11.1K
Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

400

Area of Science:

  • Neurology
  • Clinical Trials
  • Biostatistics

Background:

  • Disease-modifying therapies (DMTs) show potential in early-stage diseases like Alzheimer's, but interpreting their clinical relevance is challenging due to slow progression.
  • Standard clinical trial endpoints may not fully capture the subtle yet significant effects of DMTs.

Purpose of the Study:

  • To evaluate the utility of Time Component Tests (TCTs) in quantifying and interpreting the efficacy of DMTs for early Alzheimer's disease.
  • To demonstrate how TCTs translate treatment differences into easily understood metrics like 'time saved'.

Main Methods:

  • Applied TCT methods to a Phase II clinical trial involving 332 patients with early Alzheimer's disease.
  • Utilized composite scales (aADAS, aADL) as co-primary outcomes, alongside standard scales (CDR-sb, ADAS-Cog, ADCS-ADL).
  • Compared treatment groups receiving AFFITOPE® AD02 or AD04 with control groups.

Main Results:

  • The AD04 2 mg group showed statistically significant effects, but the clinical meaningfulness of a 3.8-point composite difference was unclear.
  • TCT analysis revealed a clinically relevant time savings of 11 months over an 18-month study period for the AD04 2 mg group.
  • This time savings metric provided a more universally understood measure of treatment effect than the composite score difference.

Conclusions:

  • A combined approach using composite outcomes and TCTs enhances the detection and interpretation of DMT effects.
  • TCTs offer a powerful, intuitive method for assessing the real-world impact of treatments for progressive neurological diseases.
  • The 'time saved' metric derived from TCTs improves the communication of clinical trial results to a broader audience.